Sirtuin Dysfunction Validation in Parkinson's Disease

Experimental Design: SIRT-PD-001

Rationale

This study tests the [Sirtuin Dysfunction Hypothesis](/mechanisms/sirtuin-signaling-neurodegeneration) by measuring sirtuin activity and NAD+ levels in [Parkinson's disease](/diseases/parkinsons-disease) patients and evaluating [SIRT1](/entities/sirt1) activator intervention. Sirtuins ([SIRT1](/entities/sirt1), [SIRT2](/entities/sirt2), [SIRT3](/entities/sirt3)) are NAD+-dependent deacetylases that regulate [mitochondrial function](/mechanisms/mitochondrial-dysfunction), [autophagy](/mechanisms/autophagy), and [neuroinflammation](/mechanisms/neuroinflammation) — all processes central to [PD pathogenesis](/diseases/parkinsons-disease).

Study Design

| Parameter | Design |
|-----------|--------|
| Type | Two-phase: observational + interventional |
| Phase 1 | Cross-sectional biomarker study |
| Phase 2 | Single-arm open-label intervention |
| Duration | 24 weeks total |
| Sample Size | 60 PD patients, 30 age-matched controls |

Phase 1: Biomarker Validation

Primary Endpoints

Secondary Endpoints

• Plasma NAD+ and NADH ratio
• Serum cytokine profile (IL-1β, TNF-α, IL-6)
• Peripheral blood mitochondrial function (Seahorse analysis)
• Clinical measures: UPDRS, MoCA, non-motor symptom scale

Experimental Design: SIRT-PD-001

Rationale

This study tests the [Sirtuin Dysfunction Hypothesis](/mechanisms/sirtuin-signaling-neurodegeneration) by measuring sirtuin activity and NAD+ levels in [Parkinson's disease](/diseases/parkinsons-disease) patients and evaluating [SIRT1](/entities/sirt1) activator intervention. Sirtuins ([SIRT1](/entities/sirt1), [SIRT2](/entities/sirt2), [SIRT3](/entities/sirt3)) are NAD+-dependent deacetylases that regulate [mitochondrial function](/mechanisms/mitochondrial-dysfunction), [autophagy](/mechanisms/autophagy), and [neuroinflammation](/mechanisms/neuroinflammation) — all processes central to [PD pathogenesis](/diseases/parkinsons-disease).

Study Design

| Parameter | Design |
|-----------|--------|
| Type | Two-phase: observational + interventional |
| Phase 1 | Cross-sectional biomarker study |
| Phase 2 | Single-arm open-label intervention |
| Duration | 24 weeks total |
| Sample Size | 60 PD patients, 30 age-matched controls |

Phase 1: Biomarker Validation

Primary Endpoints

Secondary Endpoints

• Plasma NAD+ and NADH ratio
• Serum cytokine profile (IL-1β, TNF-α, IL-6)
• Peripheral blood mitochondrial function (Seahorse analysis)
• Clinical measures: UPDRS, MoCA, non-motor symptom scale

Inclusion Criteria

• PD diagnosis (UK Brain Bank criteria)
• Hoehn & Yahr stage 1-3
• Age 50-80 years
• No SIRT1-modifying medications

Exclusion Criteria

• Active cancer
• Severe cardiovascular disease
• Diabetes (affects NAD+ metabolism)
• Prior sirtuin-based therapy

Phase 2: Intervention Study

Intervention

| Parameter | Value |
|-----------|-------|
| Compound | Nicotinamide riboside (NR) 500mg BID |
| Duration | 12 weeks |
| Monitoring | Monthly clinical assessment + biomarker sampling |

Endpoints

• Change in PBMC NAD+ from baseline
• Change in SIRT1 activity
• Change in UPDRS Part III (motor)
• Safety and tolerability

Biomarker Analysis Pipeline

Statistical Analysis

• Phase 1: Group comparisons (PD vs. control) using t-tests/Mann-Whitney
• Phase 2: Paired analysis (pre vs. post intervention)
• Correlation: Biomarker levels vs. clinical scores

Power Analysis

• 80% power to detect 30% NAD+ reduction in PD vs. controls at α=0.05
• 80% power to detect 20% NAD+ increase post-intervention at α=0.05

Expected Outcomes

Risk Mitigation

• Close monitoring for adverse events
• Exclusion of patients with contraindications
• Data safety monitoring board review at 12 weeks

Timeline

| Milestone | Timepoint |
|-----------|-----------|
| Protocol finalization | Week 0 |
| IRB approval | Week 4 |
| Enrollment complete | Week 20 |
| Phase 1 complete | Week 24 |
| Phase 2 complete | Week 36 |

Budget Estimate

| Category | Cost |
|----------|------|
| Personnel | $150,000 |
| Lab assays | $80,000 |
| Study drug | $20,000 |
| Imaging | $30,000 |
| Administrative | $20,000 |
| Total | $300,000 |

Related Mechanisms and Diseases

This experiment sits at the intersection of several key [neurodegenerative pathways](/mechanisms):

• [Parkinson's disease](/diseases/parkinsons-disease): Primary disease context — sirtuin dysfunction contributes to [dopaminergic neuron](/cell-types/dopaminergic-neurons-substantia-nigra) vulnerability
• [Alzheimer's disease](/diseases/alzheimers-disease): [SIRT1](/entities/sirt1) activation is neuroprotective in [AD models](/mechanisms/amyloid-cascade-pathway); NAD+ decline is observed in aging and [AD brains](/brain-regions/hippocampus)
• [Huntington's disease](/diseases/huntingtons): [SIRT1](/entities/sirt1) haplodeficiency modifies [mHTT](/genes/htt) toxicity; NAD+ boosting extends survival in [HD mouse models](/mechanisms/htt-transcriptional-dysregulation-pathway)
• [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction): [SIRT3](/entities/sirt3) in particular regulates mitochondrial [autophagy](/mechanisms/autophagy) and [oxidative stress](/mechanisms/oxidative-stress) responses
• [Neuroinflammation](/mechanisms/neuroinflammation): Sirtuins deacetylate [NF-κB](/mechanisms/nfkb-neurodegeneration), modulating microglial activation
• [Autophagy](/mechanisms/autophagy): SIRT1 deacetylates key [autophagy proteins](/mechanisms/autophagy-lysosome-pathway) (ATG5, ATG7, LC3); reduced NAD+ impairs autophagic flux

Key Proteins

• [SIRT1](/entities/sirt1) — nuclear sirtuin, [FOXO](/proteins/foxo1-protein) deacetylation, [PGC-1α](/entities/ppargc1a) activation
• [SIRT2](/entities/sirt2) — cytoplasmic sirtuin, [α-synuclein](/proteins/alpha-synuclein) acetylation, microtubule dynamics
• [SIRT3](/entities/sirt3) — mitochondrial sirtuin, [IDH2](/entities/idh2), [SOD2](/entities/sod2) activation

Therapeutic Targets

• [Nicotinamide riboside (NR)](/therapeutics/nicotinamide-riboside-nad-booster) — NAD+ precursor, currently in [clinical trials](/clinical-trials/) for [PD](/diseases/parkinsons-disease) and [AD](/diseases/alzheimers-disease)
• [SIRT1 activators](/therapeutics/sirt1-activating-compounds) — small molecule activators in preclinical development
• [PARP inhibitors](/mechanisms/dna-damage-response-cbs) — reduce NAD+ consumption, preserve sirtuin function

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Sirtuin Dysfunction Validation in Parkinson's Disease discovered through SciDEX knowledge graph analysis: